Malaria Birth Cohort (MBC) in Agogo, Ghana

NCT ID: NCT04050566

Last Updated: 2021-09-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1800 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-04-08

Study Completion Date

2025-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Malaria is a major health threat worldwide with an estimated 229 million cases and 409,000 deaths in 2019 (WHO, World Malaria Report 2019). Vulnerable are young children and pregnant women. The study aims to investigate immunity development against malaria with regard to parasite, human, and socioeconomic factors and possible correlations with pathology or protection in a prospective birth cohort.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Malaria during pregnancy poses substantial risks for the mother and her foetus. Due to the risk of malaria during early childhood, the study addresses the high malaria morbidity and mortality in young children. Though recognised as a public health issue, it has still not been well understood how clinical immunity against malaria parasites develops, which parasite and host factors play a role in infection susceptibility, and why some infections proceed to develop severe complications while others resolve after a mild disease.

In order to identify interactions between parasite and host, a longitudinal study is performed starting with the recruitment of pregnant women. The study is conducted in Agogo in Ghana, an area with high malaria endemicity. The study design allows to analyse the neonatal immune status at birth, after potential in-utero exposure, and follows the development of immunity over the first 36 months of life. The current paradigm is that time points and frequency of infection as well as the type of variant surface antigen expressed have an impact on the cellular and humoral immune response to malaria, the development of clinical immunity, as well as the risk for future complications.

Starting point of the study is the antenatal care visit of mothers at Agogo Presbyterian Hospital (APH) during pregnancy. During recruitment, the mother will be asked to read and sign an informed consent form approved by the local ethical committee. After consent has been obtained from the mother, biological samples are taken, and a case report form is filled. An identification card with a unique code number is handed out. The first follow-up visit occurs at the birth of the child. At this time point, samples are taken from the mothers and the child. Mothers/primary caregivers are invited to observe the EPI visits offered at their nearest health post for further follow-ups. In the first year after birth, the EPI schedule includes visits at six weeks, ten weeks, 14 weeks, six months, and nine months. During these visits, questionnaires are completed and stool samples are taken. In the first six weeks after birth, the household is visited to complete a household questionnaire including housing characteristics and household assets. Additionally, a women's questionnaire is administered, which collects demographic and socioeconomic background characteristics as well as health and related behavioural data. At 12, 18, 24, and 36 months after birth, mothers/primary caregivers are encouraged to bring their children to the study hospital (APH) for a medical check-up. For the period of 36 months after birth, mothers/primary caregivers are strongly encouraged to visit the study hospital (APH) every time the child experiences a febrile illness or a history of fever in the last week during the observation period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malaria

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mothers

900 mothers recruited during pregnancy

No interventions assigned to this group

Children

900 children born to the recruited mothers

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Catchment area of the EPI (Expanded Program of Immunization) centres with good accessibility to Agogo Prespyterian Hospital (APH)
* Willingness and able to give informed consent for herself and her child

Exclusion Criteria

* Maternal age below 18 years
* Positive HIV status of mother
* Refusal or withdrawal of informed consent
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kwame Nkrumah University of Science and Technology

OTHER

Sponsor Role collaborator

Kumasi Centre for Collaborative Research (KCCR)

OTHER

Sponsor Role collaborator

Heidelberg University

OTHER

Sponsor Role collaborator

KEMRI-Wellcome Trust Collaborative Research Program

OTHER

Sponsor Role collaborator

Agogo Presbyterian Hospital

UNKNOWN

Sponsor Role collaborator

Bernhard Nocht Institute for Tropical Medicine

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr. Jürgen May

Professor, Department Head

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jürgen May, Prof

Role: STUDY_DIRECTOR

Bernhard Nocht Institute for Tropical Medicine

John H Amuasi, Dr

Role: STUDY_DIRECTOR

Kwame Nkrumah University of Science & Technology (KNUST)

Eva Mertens, PhD

Role: PRINCIPAL_INVESTIGATOR

Bernhard Nocht Institute for Tropical Medicine

Nicole Struck, PhD

Role: PRINCIPAL_INVESTIGATOR

Bernhard Nocht Institute for Tropical Medicine

Oumou Maiga-Ascofaré, PhD

Role: PRINCIPAL_INVESTIGATOR

Kumasi Centre for Collaborative Research

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Agogo Presbyterian Hospital

Agogo, , Ghana

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Ghana

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Eva Mertens, PhD

Role: CONTACT

+49 40 42818 ext. 243

Nicole Struck, PhD

Role: CONTACT

+49 40 42818 ext. 639

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Nimako Sarpong, Dr

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PV5940

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

MiMBa Pregnancy Registry
NCT04825782 UNKNOWN
Africa Ready Malaria Screening
NCT06153862 ACTIVE_NOT_RECRUITING NA
Malaria Vaccine in Children in Mali
NCT00341250 COMPLETED PHASE1/PHASE2
Child Follow-up Until 2 Years
NCT02800109 COMPLETED